Active Specific Immunotherapy (ASI®)
    — the autologous vaccine

Active Specific Immunotherapy (ASI®), a patented therapy, which is a form of non-invasive complementary therapy/alternative therapy at an early stage, improves the malignant conditions with promising results in patients. ASI® is a therapy that attempts to stimulate specific anti-tumour responses with tumour-associated antigens as the immunising materials.

Recent immunologic studies have shown that cancer is not only a cellular disorder triggered by false genetic information but more of an immunology problem, thus, making ASI® a good choice as an immunotherapy. It is meant to bring relief from the danger of a disease’s relapse by acting as an “anti-idiotype antibody”. It is delivered to the patient as vaccination in 30 vials of 1.1 cc. each. ASI® is most commonly used in cancer cases of liver, stomach, pancreatic, breast, prostate intestine, lymphatic glands and melanoblastomas.

The ASI® autologous vaccine can also be produced from tumour tissue, however, the ideal tissue must not be exposed to any radiation at all and sent directly to the laboratory after surgery. If chemotherapy is involved prior to this, then 2 weeks must lapse before the tissue is sent to the laboratory.

The remission depends on the patient´s capacity to answer an adequate ‘challenge’ with an immunologic response.

Tissue of origin of a tumour, histological findings, size and location of the tumour, additional metabolic problems, influence of remedies or drugs, psychological anxiety, age and gender play an influencing role in deciding on the remission period.

One of the main factors of crucial influence which can severely jeopardise the effects of ASI® are chronically persisting foci. Root canal treated teeth and inflamed tonsils are the leading problems and also toxic burden, e.g. amalgam intoxication are often seen as the reason for failure in all kinds of therapies in patients with chronic degenerative or malignant disease.